Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.77 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SCN4A | P35499 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9037650 | 1.00 | S1PR5 (0.77) | S1PR5S1PR1S1PR4S1PR3LTA4H | |
| SCHEMBL16301219 | 1.00 | S1PR5 (0.77) | S1PR5S1PR1S1PR4S1PR3LTA4H | |
| Hydrochloric Acid SCHEMBL892740 | 0.98 | S1PR5 (0.75) | S1PR5S1PR1S1PR4S1PR3LTA4H | |
| Hydrochloric Acid SCHEMBL893221 | 0.98 | S1PR5 (0.75) | S1PR5S1PR1S1PR4S1PR3LTA4H | |
| Hydrochloric Acid SCHEMBL892739 | 0.98 | S1PR5 (0.75) | S1PR5S1PR1S1PR4S1PR3LTA4H | |
| Trifluoroacetic Acid SCHEMBL9038823 | 0.91 | S1PR5 (0.67) | S1PR5S1PR1S1PR4S1PR3LTA4H | |
| SCHEMBL18125935 | 0.90 | ALDH1A1 (0.71) | S1PR5S1PR1LTA4HMEN1KMT2A | |
| SCHEMBL3844177 | 0.90 | ALDH1A1 (0.71) | S1PR5S1PR1LTA4HMEN1KMT2A | |
| SCHEMBL27441592 | 0.90 | S1PR5 (0.64) | S1PR5S1PR1MEN1TSHRKMT2A | |
| SCHEMBL1519223 | 0.90 | MEN1 (0.69) | S1PR5S1PR1LTA4HMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103923765-A | Detergent Composition For Process Of Manufacturing Semiconductors And Displays | COWON INNOTECH INC | 2014-07-16 | — | — | CN | claimed |
| CN-101492421-A | Method for preparing trifluoro acetyl substituted ring amine and its derivative | SHANGHAI AQBIOPHARMA CO LTD (CN) | 2009-07-29 | — | — | CN | claimed |
| CN-113801163-B | Organic arsenic-based II-type pyruvate kinase inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2025-03-04 | — | — | CN | disclosed |
| CN-115772081-B | Preparation method of 4-ethoxy-2-methyl alkenyl butyraldehyde | 万华化学集团营养科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RESEARCH TRIANGLE INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| EP-4304630-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | Research Triangle Institute (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-116963761-A | Small molecule antagonists against relaxin-3/RXFP 3 system | 研究三角协会 | 2023-10-27 | — | — | CN | disclosed |
| CN-111808007-B | Preparation method of chiral 3-substituted pyrrolidine derivative | 青岛贞开生物医药技术有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115772081-A | Preparation method of 4-ethoxy-2-methylal | 万华化学集团股份有限公司 | 2023-03-10 | — | — | CN | disclosed |
| WO-2022192126-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RESEARCH TRIANGLE INSTITUTE (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-5693633-A | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5612360-A | AROMATIC N-HETEROCYCLIC COMPOUNDS AS HYPOTENSIVE AGENTS WITH ACID GROUPS, SULFONYLCARBOXAMIDES OR TETRAZOLE GROUPS | ELI LILLY AND COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5569768-A | USEFUL IN TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, GLAUCOMA AND RENAL INSUFFICIENCY | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5556981-A | Angiotensin II antagonist intermediates | ELI LILLY AND COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| EP-0574174-A2 | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
| US-4971958-A | CALCIUM METABOLISM | BOEHRINGER MANNHEIM GMBH (DE) | 1990-11-20 | — | — | US | disclosed |
| EP-0273190-A1 | Diphosphoric acid derivatives, process for their preparation and pharmaceuticals containing them | Roche Diagnostics GmbH (DE) | 1988-07-06 | — | — | EP | disclosed |
| EP-0174077-A1 | -9-fluoro-6,7-dihydro-5-methyl-1-oxo-8-substituted-1H,5H, benzo(ij)-quinoziline-2-carboxylic acids; their derivatives; and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-03-12 | — | — | EP | disclosed |
| US-3976660-A | Pyrrolidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RXFP3, RXFP1, RXFP4 | S1PR5 386/4885S1PR1 457/4885S1PR4 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.